Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myeloma
read at Endpoints ↗DealPositive
At ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma.
The report covered 18 patients treated with the therapy, all of whom showed encouraging outcomes, underscoring the potency of the approach.
The data comes shortly after Eli Lilly announced in April a deal worth up to $7 billion to acquire Kelonia, a move aimed at bolstering its cell-therapy pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update”
read at Endpoints ↗89 words · retrieved Jun 1
comments(0)
5-min edit window · permanent after that